Table 3 Multivariable analysis performed for the prediction of the primary outcome in (1) sub-group of patients with LVEF ≤ 35%, (2) sub-group of patients with LVEF > 35%.

From: Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy

LVEF strata

Hazard ratio (95% CI)

P

LVEF ≤ 35%

Diabetes

2.44 (1.45–4.11)

0.001

NYHA III/IV

1.69 (1.04–2.74)

0.035

LV indexed mass (per 1 g/m2 increase)

1.01 (1.00–1.02)

0.081

LVEF > 35%

Sex (male)

0.28 (0.14–0.55)

< 0.001

Diabetes

2.06 (0.974–4.37)

0.06

Hypertension

1.99 (1.01–3.91)

0.05

ACE-i/ARB

2.38 (0.81–6.96)

0.115

RVEF (per 1% increase)

0.95 (0.91–0.98)

0.006

MWS pattern fibrosis

2.40 (1.20–4.78)

0.013

  1. Variables included in the stepwise multivariate model include age, sex, body mass index, diabetes, hypertension, NYHA III/IV, ACE-inhibitor/ARB use, beta-blocker use, LVEF, RVEF, indexed LV mass and MWS fibrosis.
  2. NYHA New York heart association, RVEF right ventricular ejection fraction, MWS mid-wall fibrosis.
  3. The "bold" means that the p-value is statistically significant at < 0.05.
Back to article page